We are glad to report that in a recently published EMBO Journal...
SARS-CoV-2 Spike Trimerbody could represent a therapeutic option for COVID-19.
14-10-2021
We are glad to report that in a recently published EMBO Journal paper “Neutralization of SARS-CoV-2 by highly potent, hyperthermostable, and mutation-tolerant nanobodies” (https://doi.org/10.15252/embj.2021107985) the authors suggest that a Trimerbody against the receptor-binding domain (RBD) of the SARS-CoV-2 Spike protein could represent a therapeutic option for COVID-19.
Diario ABC España y Cadena Cope: Investigadores crean un nuevo anticuerpo antitumoral más eficaz
01-06-2021
El director de la unidad de inmunoterapia del cáncer del Instituto de Investigación del Hospital 12 de Octubre, Luis Álvarez-Vallina, ha explicado el diseño de un nuevo anticuerpo que potencia la respuesta del sistema inmunitario frente a las células tumorales y elimina las reacciones adversas asociadas a los tratamientos convencionales. (Fuente: Madrid Salud)
https://www.abc.es/espana/abci-investigadores-crean-nuevo-anticuerpo-ant...
Leadartis to present on May 26th, 2021 its business to the 17th Annual Anglonordic Life Science Conference
20-05-2021
Anglonordic is a great event to meet quality investors and companies - it is very well run and given the invitation only status it is well attended with quality investors and companies. This year we're excited since we can extend our reach to such a global and expert audience.
https://www.anglonordiclifescience.com/page/conferenceagenda
Clave Capital invests in Leadartis in a funding round of more than €1,600,000
14-05-2021
Clave Capital, through the fund Navarra Tech Transfer, consolidates with this new operation its commitment in the field of human health, in this case, together with Sodena and Capital Cell.http://capital-riesgo.es/es/articles/clave-invierte-en-leadartis-en-una-ronda-de-financiaci-n-de-m-s-de-1-600-000/
Sodena and Capital Cell invest €1.600.000 in the biopharmaceutical Leadartis
30-04-2021
The entry of funds into leadartis' shareholding is part of a round of financing closed by the company in recent times. "An action that has endowed it with 1.6 million euros that will advance the development of the first immunotherapy candidate against advanced cancers with high medical need such as lung, colon and breast."
Leadartis reaches a major milestone with the demonstration of absence of toxicity of its drug candidate in preclinical models
13-01-2021
Leadartis reaches a major milestone with the demonstration of absence of toxicity of its EGFR-targeted 4-1BB-agonistic bispecific Trimerbody which does not Induce Hepatotoxicity in transgenic mice with liver expression of human EGFR (https://www.frontiersin.org/articles/10.3389/fimmu.2020.614363/full).
Leadartis closes the investment round in 14 days with an overfunding of 25%
28-09-2020
We are pleased to inform you that the investment round has been successfully closed, raising a total of € 1,250,000 euros, equivalent to 125% of the published goal of 1,000,000 euros. https://capitalcell.es/campaign/leadartis/. We will provide you with additional details as we complete the formalities.
Thank you very much for your participation.
Juan J. Perez Villar, Leadartis CEO
Latest News
|
SARS-CoV-2 Spike Trimerbody could represent a therapeutic option for COVID-19.
14-10-2021
|
"Tumor-targeted costimulatory trimerbodies for cancer Immunotherapy”- A brief discussion with Juan Perez Villar, CEO, LEADARTIS.
07-06-2021
... |
Diario ABC España y Cadena Cope: Investigadores crean un nuevo anticuerpo antitumoral más eficaz
01-06-2021
El director de la unidad de inmunoterapia del cáncer del Instituto de Investigación del Hospital... |
